Not Yet RecruitingPhase 1

Oral Dexmedetomidine in Pediatric MRI

United States18 participantsStarted 2026-06-01

Plain-language summary

The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.

Who can participate

Age range3 Years – 6 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants 3-6 years old, male and female, all races and ethnicities
✓. Requiring a clinically indicated MRI with general anesthesia

Exclusion criteria

✕. Refusal to take oral dexmedetomidine
✕. Known allergy to dexmedetomidine
✕. Inability to take dexmedetomidine at least 90 minutes prior to start of the MRI
✕. Medical contraindications to administration of dexmedetomidine including:
✕. Unstable cardiac status including life threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction
✕. Current use of digoxin
✕. Moya Moya disease
✕. New onset stroke

What they're measuring

Oral dexmedetomidine dose with adverse event below moderate risk, as designated by SIVA, to obtain adequate MRI study

Timeframe: From date of the first enrollment until the end of assessment of data collected from the last participant, up to 70 weeks

Trial details

NCT IDNCT05619627

SponsorSoroush Merchant

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06

Contact for this trial

Soroush Merchant, MD, MS

816-3018595 smerchant@cmh.edu

View on ClinicalTrials.gov More Anesthesia trials